A New In-Vitro Diagnostic to predict the response to Gemcitabine treatment in pancreatic cancer

Acobiom proposes a new In-Vitro Diagnostic (IVD), based on a new Blood RNA-biomarker signature, able to predict the response to Gemcitabine in Metastatic Pancreatic Cancer and to prognose a 14.9-month survival.

Acobiom discovered and patented a set of blood  RNA-biomarkers that are correlated to a 14.9-month survival prognosis in Pancreatic Cancer patients treated by Gemcitabine.

From this new Blood RNA-biomarker signature, Acobiom developed a new In-Vitro Diagnostic, called GemciTest, based on qRT-PCR technology.

Hence, the GemciTest can identify the patients suffered from pancreatic cancer that are the most likely to benefit from gemcitabine.

To illustrate the overall survival benefits of the GemciTest, the sub-population of patients identified by the GemciTest is characterized by the following rates:

> 65% of them are alive 12 months after the diagnostic of the disease (versus 35%* for the patients treated by the combination Abraxane+Gemcitabine and 24% for the patients treated blindly by gemcitabine),
> 50% of them are alive 14.9 months after the diagnostic of the disease (versus 20%* for the patients treated by the combination Abraxane+Gemcitabine and 11% for the patients treated blindly by gemcitabine).

(*: data from « Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine », Von Hoff et al, N Engl J Med. 2013)

Acobiom GemciTest OS pub.OK

The benefits of the GemciTest on clinical and economical aspects are described on the following document: The Gemcitest flyer and in the following presentation: Gemcitest

The SOP of the GemciTest is available for routine analyses and the diagnostic can be ordered for « Research Use Only » (RUO).

If you need more information, please contact our business development department (T: +33(0)467 419 748, Email: busdev@acobiom.com).